Gsa Capital Partners LLP Bluebird Bio, Inc. Transaction History

Gsa Capital Partners LLP

  • $1.32 Billion
  • Q3 2024

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 16, 2024
BUY
$1.32 - $4.83 $28,055 - $102,656
21,254 New
21,254 $29,000
Q1 2023

May 12, 2023
BUY
$3.14 - $8.22 $265,251 - $694,384
84,475 Added 636.68%
97,743 $310,000
Q4 2022

Feb 13, 2023
SELL
$5.77 - $8.49 $798,002 - $1.17 Million
-138,302 Reduced 91.25%
13,268 $92,000
Q3 2022

Nov 14, 2022
BUY
$3.75 - $7.39 $568,387 - $1.12 Million
151,570 New
151,570 $959,000
Q2 2022

Aug 09, 2022
SELL
$2.94 - $5.23 $58,106 - $103,365
-19,764 Closed
0 $0
Q1 2022

May 11, 2022
BUY
$4.07 - $10.6 $80,439 - $209,498
19,764 New
19,764 $96,000
Q3 2021

Nov 12, 2021
SELL
$11.24 - $21.0 $137,015 - $255,990
-12,190 Closed
0 $0
Q2 2021

Aug 05, 2021
SELL
$18.04 - $22.09 $1.4 Million - $1.72 Million
-77,810 Reduced 86.46%
12,190 $390,000
Q1 2021

May 10, 2021
BUY
$16.59 - $33.89 $1.49 Million - $3.05 Million
90,000 New
90,000 $2.71 Million
Q2 2020

Aug 11, 2020
SELL
$27.12 - $45.97 $174,924 - $296,506
-6,450 Closed
0 $0
Q1 2020

May 12, 2020
BUY
$26.16 - $63.5 $168,732 - $409,575
6,450 New
6,450 $296,000
Q2 2018

Aug 09, 2018
SELL
$99.64 - $127.59 $2.03 Million - $2.6 Million
-20,409 Closed
0 $0
Q1 2018

May 11, 2018
BUY
$105.8 - $150.94 $2.16 Million - $3.08 Million
20,409 New
20,409 $3.49 Million

Others Institutions Holding BLUE

# of Institutions
151
Shares Held
63.4M
Call Options Held
264K
Put Options Held
428K
View Full List

About bluebird bio, Inc.

BLUE Quotes by TradingView
  • Ticker BLUE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,121,800
  • Market Cap $23.1M
  • Description
  • bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...
More about BLUE
Track This Portfolio

Track Gsa Capital Partners LLP Portfolio

Follow Gsa Capital Partners LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Gsa Capital Partners LLP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email